TRIM24 and cancer: Older age was significantly associated with cancer onset [HR 1.04 (95% CI 1.02, 1.07)]; the significant association between anti-TIF1-Ab positivity and early cancer onset only existed for those ≥39 years of age [HR 4.1 (95% CI 2.5, 6.7) vs HR 0.8 (95% CI 0.1, 6.5) for patients ≥39 and <39 years of age, respectively].